Concepedia

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella, Ashish M. Kamat, Trinity J. Bivalacqua, Jeffrey S. Montgomery, Seth P. Lerner, Joseph E. Busby,

The Lancet Oncology · 2020 · 442 citations · 23 references

DOIFull text

Open access

Concepts

References

23

MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY

Donald L. Lamm, Brent A. Blumenstein, John D. Crissman et al. · The Journal of Urology · 2000 · 1.3K citations

, , +11

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Sam S. Chang, Bernard H. Bochner, Roger Chou et al. · The Journal of Urology · 2017 · 940 citations · Full text

, , +13

ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group.

PubMed · 1999 · 313 citations

, , +11

Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study

Neal D. Shore, Stephen A. Boorjian, Daniel Canter et al. · Journal of Clinical Oncology · 2017 · 172 citations · Full text

, , +17

SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Guérin

Eila C. Skinner, Bryan Goldman, Wael Sakr et al. · The Journal of Urology · 2013 · 161 citations

, , +11